Chemotherapy for recurrent cervical cancer

Gynecologic Oncology

Volumn 107, Issue 1 SUPPL., 2007, Pages

  Cadron, Isabelle ^a   Van Gorp, Toon ^a   Amant, Frederic ^a   Leunen, Karin ^a   Neven, Patrick ^a   Vergote, Ignace ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chemotherapy; Cisplatin; Recurrent cervical cancer

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; IPROPLATIN; IRINOTECAN; LOMUSTINE; MELPHALAN; METHOTREXATE; NAVELBINE; PACLITAXEL; PLATINUM; TOPOTECAN; VINBLASTINE; VINCRISTINE; VINDESINE;

ADJUVANT THERAPY; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RADIOSENSITIVITY; RECURRENT CANCER; UTERINE CERVIX CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; TOPOTECAN; UTERINE CERVICAL NEOPLASMS;

EID: 34848842757     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.07.004     Document Type: Article

References (71)

1. SEER Cancer Statistics. Estimated new cancer cases and deaths for 2007. NCI (2007) Ref Type: Internet Communication
2. Berek J.S., and Hacker N.F. Practical gynaecologic oncology (2005), Lippincott Williams & Wilkins, New York
3. Bonomi P., Blessing J.A., Stehman F.B., DiSaia P.J., Walton L., and Major F.J. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3 8 (Aug 1985) 1079-1085
4. Long III H.J., Bundy B.N., Grendys Jr. E.C., Benda J.A., McMeekin D.S., Sorosky J., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23 21 (Jul 20 2005) 4626-4633
5. Peters III W.A., Liu P.Y., Barrett R.J., Stock R.J., Monk B.J., Berek J.S., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18 8 (Apr 2000) 1606-1613
6. Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., Hannigan E.V., Fowler Jr. W.C., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17 5 (May 1999) 1339-1348
7. Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., Stevens R.E., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340 15 (Apr 15 1999) 1137-1143
8. Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340 15 (Apr 15 1999) 1144-1153
9. Pearcey R., Brundage M., Drouin P., Jeffrey J., Johnston D., Lukka H., et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 20 4 (Feb 15 2002) 966-972
10. Green J.A., Kirwan J.M., Tierney J.F., Symonds P., Fresco L., Collingwood M., et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358 9284 (Sep 8 2001) 781-786
11. Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., Chafe W.E., Suggs III C.L., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340 15 (Apr 15 1999) 1154-1161
12. Cochrane Database of Systematic Reviews. Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration (NACCCMA) Collaboration. Neoadjuvant chemotherapy for locally advanced cervix cancer (Jan 26 2004), John Wiley & Sons
13. Thigpen T., Shingleton H., Homesley H., Lagasse L., and Blessing J. cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group. Cancer Treat Rep 63 9-10 (Sep 1979) 1549-1555
14. McGuire III W.P., Arseneau J., Blessing J.A., DiSaia P.J., Hatch K.D., Given Jr. F.T., et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 7 10 (Oct 1989) 1462-1468
15. Kaern J., Trope C., Abeler V., Iversen T., and Kjorstad K. A phase II study of 5-fluorouracil/cisplatinum in recurrent cervical cancer. Acta Oncol 29 1 (1990) 25-28
16. Kaern J., Trope C., Sundfoer K., and Kristensen G.B. Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up. Gynecol Oncol 60 3 (Mar 1996) 387-392
17. Wade J.L., Richman C.M., and Snekjian E. Objective response in advanced carcinoma of the cervix using cis-platinum and infusion 5-fluorouracil chemotherapy. Proc Am Soc Clin Oncol 3 172 (1984) [Ref Type: Abstract]
18. Bonomi P., Blessing J., Ball H., Hanjani P., and DiSaia P.J. A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 34 3 (Sep 1989) 357-359
19. Blackledge G., Buxton E.J., Mould J.J., Monaghan J., Paterson M., Tobias J., et al. Phase II studies of ifosfamide alone and in combination in cancer of the cervix. Cancer Chemother Pharmacol 26 Suppl (1990) S12-S16
20. Thigpen T., Vance R., Khansur T., and Malamud F. The role of ifosfamide and systemic therapy in the management of carcinoma of the cervix. Semin Oncol 23 3 Suppl 6 (Jun 1996) 56-64
21. Sutton G.P., Blessing J.A., Photopulos G., Berman M.L., and Homesley H.D. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies. Semin Oncol 16 1 Suppl 3 (Feb 1989) 68-72
22. Sutton G.P., Blessing J.A., Adcock L., Webster K.D., and DeEulis T. Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study. Invest New Drugs 7 4 (Nov 1989) 341-343
23. Stehman F.B., Blessing J.A., McGehee R., and Barrett R.J. A phase II evaluation of mitolactol in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 7 12 (Dec 1989) 1892-1895
24. Omura G.A., Blessing J.A., Vaccarello L., Berman M.L., Clarke-Pearson D.L., Mutch D.G., et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 15 1 (Jan 1997) 165-171
25. Ramm K., Vergote I.B., Kaern J., and Trope C.G. Bleomycin-ifosfamide-cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: a second look. Gynecol Oncol 46 2 (Aug 1992) 203-207
26. Kumar L., and Bhargava V.L. Chemotherapy in recurrent and advanced cervical cancer. Gynecol Oncol 40 2 (Feb 1991) 107-111
27. Buxton E.J., Meanwell C.A., Hilton C., Mould J.J., Spooner D., Chetiyawardana A., et al. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst 81 5 (Mar 1 1989) 359-361
28. Murad A.M., Triginelli S.A., and Ribalta J.C. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol 12 1 (Jan 1994) 55-59
29. Bloss J.D., Blessing J.A., Behrens B.C., Mannel R.S., Rader J.S., Sood A.K., et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 20 7 (Apr 1 2002) 1832-1837
30. Cadron I., Jakobsen A., and Vergote I. Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/5-fluorouracil in recurrent cervical cancer. Gynecol Obstet Invest 59 3 (2005) 126-129
31. Curtin J.P., Blessing J.A., Webster K.D., Rose P.G., Mayer A.R., Fowler Jr. W.C., et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 19 5 (Mar 1 2001) 1275-1278
32. McGuire W.P., Blessing J.A., Moore D., Lentz S.S., and Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 14 3 (Mar 1996) 792-795
33. Ota S., Sugiyama T., Ushijima K., Fujiyoshi K., Komai K., Hirai N., et al. Remission of metastatic cervical adenocarcinoma with weekly paclitaxel. Int J Gynecol Cancer 11 2 (Mar 2001) 167-168
34. Zanetta G., Fei F., and Mangioni C. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza. Semin Oncol 27 1 Suppl 1 (Feb 2000) 23-27
35. Dimopoulos M.A., Papadimitriou C.A., Sarris K., Aravantinos G., Kalofonos C., Gika D., et al. Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group. Gynecol Oncol 85 3 (Jun 2002) 476-482
36. Choi C.H., Kim T.J., Lee S.J., Lee J.W., Kim B.G., Lee J.H., et al. Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer 16 3 (May 2006) 1157-1164
37. Rose P.G., Blessing J.A., Gershenson D.M., and McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 17 9 (Sep 1999) 2676-2680
38. Moore D.H., Blessing J.A., McQuellon R.P., Thaler H.T., Cella D., Benda J., et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22 15 (Aug 1 2004) 3113-3119
39. Sit A.S., Kelley J.L., Gallion H.H., Kunschner A.J., and Edwards R.P. Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix. Cancer Invest 22 3 (2004) 368-373
40. Tinker A.V., Bhagat K., Swenerton K.D., and Hoskins P.J. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience. Gynecol Oncol 98 1 (Jul 2005) 54-58
41. Nagao S., Fujiwara K., Oda T., Ishikawa H., Koike H., Tanaka H., et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol 96 3 (Mar 2005) 805-809
42. Hainsworth J.D., Burris III H.A., Meluch A.A., Baker M.N., Morrissey L.H., and Greco F.A. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial. Cancer 92 3 (Aug 1 2001) 642-649
43. Tiersten A.D., Selleck M.J., Hershman D.L., Smith D., Resnik E.E., Troxel A.B., et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol 92 2 (Feb 2004) 635-638
44. Hernandez P., Olivera P., Duenas-Gonzalez A., Perez-Pastenes M.A., Zarate A., Maldonado V., et al. Gemcitabine activity in cervical cancer cell lines. Cancer Chemother Pharmacol 48 6 (Dec 2001) 488-492
45. Peters G.J., Bergman A.M., Ruiz vH V., Veerman G., Kuiper C.M., and Braakhuis B.J. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 4 Suppl 11 (Aug 1995) 72-79
46. Mutch D.G., and Bloss J.D. Gemcitabine in cervical cancer. Gynecol Oncol 90 2 Pt 2 (Aug 2003) S8-S15
47. Schilder R.J., Blessing J., and Cohn D.E. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 96 1 (Jan 2005) 103-107
48. Lhomme C., Vermorken J.B., Mickiewicz E., Chevalier B., Alvarez A., Mendiola C., et al. Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study. Eur J Cancer 36 2 (Jan 2000) 194-199
49. Morris M., Blessing J.A., Monk B.J., McGehee R., and Moore D.H. Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22 16 (Aug 15 2004) 3340-3344
50. Monk B.J., Huang H.Q., Cella D., and Long III H.J. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23 21 (Jul 20 2005) 4617-4625
51. Meanwell C.A., Mould J.J., Blackledge G., Lawton F.G., Stuart N.S., Kavanagh J., et al. Phase II study of ifosfamide in cervical cancer. Cancer Treat Rep 70 6 (Jun 1986) 727-730
52. Smith J.P., Rutledge F., Burns Jr. B.C., and Soffar S. Systemic chemotherapy for carcinoma of the cervix. Am J Obstet Gynecol 97 6 (Mar 15 1967) 800-807
53. Moore G.E., Bross I.D., Ausman R., Nadler S., Jones Jr. R., Slack N., et al. Effects of chlorambucil (NSC-3088) in 374 patients with advanced cancer. Eastern Clinical Drug Evaluation Program. Cancer Chemother Rep 52 6 (Oct 1968) 661-666
54. Wasserman T.H., and Carter S.K. The integration of chemotherapy into combined modality treatment of solid tumors: VIII. Cervical cancer. Cancer Treat Rev 4 1 (Mar 1977) 25-46
55. Moore G.E., Bross I.D., Ausman R., Nadler S., Jones Jr. R., Slack N., et al. Effects of mitomycin c (NSC-26980) in 346 patients with advanced cancer. Eastern Clinical Drug Evaluation Program. Cancer Chemother Rep 52 6 (Oct 1968) 675-684
56. Kato T., Abe H., Yamagami T., and Uchino M. Therapeutic effects of bleomycin, an anticarcinogenic agent, on cancers of the female genital organs. Kurume Med J 17 2 (1970) 75-95
57. Omura G.A., Shingleton H.M., Creasman W.T., Blessing J.A., and Boronow R.C. Chemotherapy of gynecologic cancer with nitrosoureas: a randomized trial of CCNU and methyl-CCNU in cancers of the cervix, corpus, vagina, and vulva. Cancer Treat Rep 62 5 (May 1978) 833-835
58. Cavins J.A., and Geisler H.E. Treatment of advanced, unresectable, cervical carcinoma already subjected to complete irradiation therapy. Gynecol Oncol 6 3 (Jun 1978) 256-260
59. van der Burg M.E., Monfardini S., Guastalla J.P., de O.C., Renard J., and Vermorken J.B. Phase II study of weekly 4′-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix: an EORTC Gynaecological Cancer Cooperative Group Study. Eur J Cancer 29A 1 (1992) 147-148
60. Muderspach L.I., Blessing J.A., Levenback C., and Moore Jr. J.L. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 81 2 (May 2001) 213-215
61. Verschraegen C.F., Levy T., Kudelka A.P., Llerena E., Ende K., Freedman R.S., et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 15 2 (Feb 1997) 625-631
62. Malkasian Jr. G.D., Decker D.G., Mussey E., and Johnson C.E. Chemotherapy of squamous cell carcinoma of the cervix, vagina, and vulva. Clin Obstet Gynecol 11 2 (Jun 1968) 367-381
63. Tejada F., Casanova L., Galdos R., Barriga O., Olivares A., Solidoro A., et al. Programmed chemotherapy of cervical carcinoma. Proc Am Assoc Cancer Res 22 162 (1981) [Ref Type: Abstract]
64. Rhomberg W.U. Vindesine for recurrent and metastatic cancer of the uterine cervix: a phase II study. Cancer Treat Rep 70 12 (Dec 1986) 1455-1457
65. Hreshchyshyn M. Vincristine treatment of patients with carcinoma of the uterine cervix. Proc Am Assoc Cancer Res 4 29 (2007) [Ref Type: Abstract]
66. Kavanagh J.J., Saul P.B., Gershenson D.M., Copeland L.J., and Wharton J.T. Continuous-infusion vindesine in refractory carcinoma of the cervix: a phase II trial. Cancer Treat Rep 69 11 (Nov 1985) 1317-1318
67. Kudelka A.P., Verschraegen C.F., Levy T., Edwards C.L., Fishman A., Freedman R.S., et al. Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 7 4 (Jun 1996) 398-401
68. Lorvidhaya V., Kamnerdsupaphon P., Chitapanarux I., Sukthomya V., and Tonusin A. Cisplatin and gemcitabine in patients with metastatic cervical cancer. Gan To Kagaku Ryoho 31 7 (Jul 2004) 1057-1062
69. Fiorica J.V. Update on the treatment of cervical and uterine carcinoma: focus on topotecan. Oncologist 7 Suppl 5 (2002) 36-45
70. Serkies K., Jassem J., and Dziadziuszko R. Chemotherapy with mitomycin c, ifosfamide, and cisplatin for recurrent or persistent cervical cancer. Int J Gynecol Cancer 16 3 (May 2006) 1152-1156
71. Maluf F.C., Leiser A.L., Aghajanian C., Sabbatini P., Pezzulli S., Chi D.S., et al. Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. Int J Gynecol Cancer 16 3 (May 2006) 1165-1171